(Q40648327)

English

Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure

scientific article published on 23 April 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure (English)

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

author name string

Fahd Quddus

1

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Jessica Clima

2

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Helen Seedham

3

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Ghulam Sajjad

4

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Naomi Galili

5

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Azra Raza

6

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

publication date

23 April 2010

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Journal of Hematology & Oncology

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

3

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

16

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873355

22 September 2017

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873355

22 September 2017

How I treat patients with myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873355

22 September 2017

Current treatment options: impact of cytogenetics on the course of myelodysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873355

22 September 2017

Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2873355

22 September 2017

Identifiers

10.1186/1756-8722-3-16

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1756-8722-3-16

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40648327&oldid=2203858686"